Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its ...

Astra said a trial of its Enhertu treatment showed the drug demonstrated a 'highly statistically significant' improvement on ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Condor Partners and Northlight Capital Partners, with JP Partners brokering the deal, are pleased to announce new funding for Mural Park, a 200,000-square-foot, Class A office project in Chicago, ...

The benchmark FTSE 100, which advanced to 8,317.42 earlier ... The pharma major reported positive results for its breast cancer treatment Enhertu. Pershing Square Holdings, Scottish Mortgage ...

Tukysa brought in just under $100 million in the second quarter ... from AstraZeneca and Daiichi Sankyo's rival HER2 ADC Enhertu (trastuzumab deruxtecan), which outperformed Kadcyla in a head ...

“We expect to have more than 100 vaccination experts on the ground ... New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer ...

for a new indication for Enhertu Footnote * (trastuzumab deruxtecan), powder for concentrate for solution for intravenous infusion, 100 mg. The new indication for Enhertu, as monotherapy, is for the ...